Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreak 201: Sotorasib in First-Line KRAS G12C-Mutated Stage IV NSCLC
2024-511189-36-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Objective response (OR). Started Dec 2021; status: completed.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511189-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511189-36-00.